Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway

A glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (LR) had been experimentally and clinically shown to ameliorate nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the beneficial effect of LR on NAFLD in vivo and in vitro and its underlying molecular mechanism. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Peng, Xu, Xi, Zhang, Jing, Xia, Xuan, Xu, Fen, Weng, Jianping, Lai, Xiaoyang, Shen, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545813/
https://www.ncbi.nlm.nih.gov/pubmed/31236111
http://dx.doi.org/10.1155/2019/1567095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545813/
https://www.ncbi.nlm.nih.gov/pubmed/31236111
http://dx.doi.org/10.1155/2019/1567095

Ejemplares similares